Certified by Founder
Lodge
smartbax
start up
Germany
- München
- 24/05/2023
- Seed
- $1,291,000
smartbax develops novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms. With the first-in-class compounds, the company targets the multi-drug resistant pathogens methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
- Industry Biotechnology Research
- Website https://www.smartbax.de/
- LinkedIn https://www.linkedin.com/company/smartbax-gmbh/
Advance | $8,550,000 | (Feb 6, 2026)
Turnstile | $29,000,000 | (Feb 6, 2026)
Accrual | $75,000,000 | (Feb 6, 2026)
Connect Music | $80,000,000 | (Feb 6, 2026)
adaption | $50,000,000 | (Feb 6, 2026)
Cadastral | $9,500,000 | (Feb 6, 2026)
Nixtla | $16,000,000 | (Feb 6, 2026)
Nullify | $12,500,000 | (Feb 6, 2026)
Uplift360 | $8,724,008 | (Feb 6, 2026)
Fundamental | $255,000,000 | (Feb 6, 2026)
Duna | $35,365,500 | (Feb 6, 2026)
Flock AI | $6,000,000 | (Feb 6, 2026)